Biopharma, Competition and Pharma

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

NOVEMBER 25, 2024

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

Trending Sources

The New Radiopharma Competition Requires Unprecedented Medical Logistics

FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice

Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas

Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator

Sanofi’s FDA Nod in Hemophilia Gives Patients More Convenience, Brings Roche New Competition

How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance

Sanofi drops out of competitive breast cancer drug race after another trial failure

Innovation key for boosting UK biopharma competitiveness

Cytokinetics Heart Drug’s Trial Data Look Competitive With BMS Med Camzyos

FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med

Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda

Structure Raises $300M as Oral GLP-1 Drug’s Data Keep Up With Pfizer, Eli Lilly

Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients

The perfect storm is coming for pharma

Amarin Restructures, Charting Course That Braces for Generic Competition

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach

FDA Approval of Pfizer Alopecia Drug Brings New Competition to Eli Lilly Med

TheracosBio Drug Approval Puts It in Competition With Blockbuster Diabetes Meds

Boehringer Ingelheim’s Liver Drug Data Position It for MASH Clash With Eli Lilly

Pharma Injecting Life into Digital Health Amidst Funding Downturn

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance

Biopharma struggling to find talent with adequate digital skills

Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers

Amgen to Buy Horizon Therapeutics for $28B, Edging Out Sanofi in Bidding War

Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss Drugs

Sanofi Abandons Deal for Rare Disease Drug Amid FTC’s Monopoly Concerns

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

A biologic’s efficacy in a pill: Dice posts first human data for oral psoriasis med

FTC Files Suit to Block Amgen’s $28B Buyout of Horizon Therapeutics

J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS

Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer

Trends in biopharma contract manufacturing 2022

Stay Connected